Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection
AbstractHepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. The interplay between the virus and host innate and adaptive immune responses determines the outcome of infection. There is increasing evidence that host neutralizing responses play a relevant role in the resulting pathogenesis. Furthermore, viral evasion from host neutralizing antibodies has been revealed to be an important contributor in leading both to viral persistence in acute liver graft infection following liver transplantation, and to chronic viral infection. The development of novel model systems to study HCV entry and neutralization has allowed a detailed understanding of the molecular mechanisms of virus-host interactions during antibody-mediated neutralization. The understanding of these mechanisms will ultimately contribute to the development of novel antiviral preventive strategies for liver graft infection and an urgently needed vaccine. This review summarizes recent concepts of the role of neutralizing antibodies in viral clearance and protection, and highlights consequences of viral escape from neutralizing antibodies in the pathogenesis of HCV infection. View Full-Text
Share & Cite This Article
Fafi-Kremer, S.; Fauvelle, C.; Felmlee, D.J.; Zeisel, M.B.; Lepiller, Q.; Fofana, I.; Heydmann, L.; Stoll-Keller, F.; Baumert, T.F. Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection. Viruses 2012, 4, 2016-2030.
Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF. Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection. Viruses. 2012; 4(10):2016-2030.Chicago/Turabian Style
Fafi-Kremer, Samira; Fauvelle, Catherine; Felmlee, Daniel J.; Zeisel, Mirjam B.; Lepiller, Quentin; Fofana, Isabel; Heydmann, Laura; Stoll-Keller, Françoise; Baumert, Thomas F. 2012. "Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection." Viruses 4, no. 10: 2016-2030.